The standard of care for severe hemophilia A is regular replacement therapy (prophylaxis) with clotting factor concentrates (e.g., recombinant FVIII protein) or other hemostasis products to prevent bleeding; on-demand treatment with clotting factor replacement therapy in instances of acute bleeding is available but is not considered to be a long-term treatment option. Here, F8 is linked to hemophilia A.